Hyaluronic acid for anticancer drug and nucleic acid delivery

详细信息    查看全文

• 作者：Franco Dosio^a ; ^{franco.dosio@unito.it" class="auth_mail" title="E-mail the corresponding author} ; Silvia Arpicco^a ; ^{silvia.arpicco@unito.it" class="auth_mail" title="E-mail the corresponding author} ; Barbara Stella^a ; ^{barbara.stella@unito.it" class="auth_mail" title="E-mail the corresponding author} ; Elias Fattal^b ; ^c ; ^{elias.fattal@u-psud.fr" class="auth_mail" title="E-mail the corresponding author}
• 关键词：ADH ; adipic acid dihydrazide ; AUNPs ; gold nanoparticles ; BA ; butyric acid ; CDDP ; cisplatin ; CHI ; chitosane ; CNTs ; carbon nanotubes ; CPT ; camptothecin ; CSCs ; cancer stem cells ; DiPhPE ; diphytanoyl-sn-glycero-3-glycerophosphatidyl ethanolamine ; DL ; drug loading (%w/w)  ; =  ; (mass drug in system/whole mass of system) *100 ; DLPE ; 1 ; 2-dilauroyl-sn-glycero-3-phosphatidyl ethanolamine ; DMPE ; 1 ; 2-dimiristoyl-sn-glycero-3-glycerophosphatidyl ethanolamine ; DOCA ; deoxycholic acid ; DOPE ; 1 ; 2-dioleoyl-
• 刊名：Advanced Drug Delivery Reviews
• 出版年：2016
• 出版时间：1 February 2016
• 年：2016
• 卷：97
• 期：Complete
• 页码：204-236
• 全文大小：1979 K

文摘

Hyaluronic acid (HA) is widely used in anticancer drug delivery, since it is biocompatible, biodegradable, non-toxic, and non-immunogenic; moreover, HA receptors are overexpressed on many tumor cells. Exploiting this ligand-receptor interaction, the use of HA is now a rapidly-growing platform for targeting CD44-overexpressing cells, to improve anticancer therapies. The rationale underlying approaches, chemical strategies, and recent advances in the use of HA to design drug carriers for delivering anticancer agents, are reviewed. Comprehensive descriptions are given of HA-based drug conjugates, particulate carriers (micelles, liposomes, nanoparticles, microparticles), inorganic nanostructures, and hydrogels, with particular emphasis on reports of preclinical/clinical results.